Navigation Links
US Drugmaker Slapped Huge Fine for Misleading Doctors Over Addictive Painkiller

After four years of unrelenting pursuit by the Food and Drug Administration, the Purdue pharma of the US gave in, admitting it had made false claims about their popular painkiller Oxycontin.

They have agreed to pay up $634.5 millions for making false claims about the drug to boost sales and also pleaded guilty to charges of playing down Oxycontins addictive and euphoric properties.

Purdue pleaded guilty to a felony count of misbranding a drug with intent to defraud and mislead.

Under the agreement, it will pay a $600 million settlement, including a criminal fine, restitution to government agencies, and more than $276 million in forfeiture. In a separate civil settlement, Purdue will pay $100.6 million.

According to an investigation by the Food and Drug Administration (FDA)s Office of Criminal Investigations (OCI), the drug company trained its sales force to represent OxyContin as a drug that did not cause euphoria and was less addictive than immediate-release opiates; and allowed healthcare providers to have the mistaken notion that OxyContin was less addictive than morphine.

Over the last few years there have been instances of hundreds of overdose deaths linked to OxyContin's main ingredient oxycodone. The drug was marketed as a miracle pain reliever; less addictive and less subject to abuse than similar medications. However, it was later found that its contents could be highly addictive and even fatal.

Purdue Pharma also made false representations about the difficulty of extracting oxycodone, the active ingredient, from the OxyContin tablet, and labeled the drug as providing fewer peaks and valleys than with immediate-release oxycodone, the OCI said.

U.S. Attorney John Brownlee said, "With its OxyContin, Purdue unleashed a highly abusable, addictive, and potentially dangerous drug on an unsuspecting and unknowing public."

"For these misrepresentations and crimes, Purdue a nd its executives have been brought to justice."

OxyContin is a trade name for oxycodone, and is a time-release painkiller that can be highly addictive. In that variety the ingredients are released over a period of time for sustained effect.

The drug is meant to be swallowed whole and digested over 12 hours. It was later found that the pills can produce a heroin-like high if crushed and then swallowed, snorted or injected.

According to the Drug Enforcement Agency (DEA), the number of deaths linked to the use of OxyContin jumped 400 percent between 1996 and 2001. Still, in 2001, Purdue executives testified they had just become aware that the drug was being abused.

In its statement, Purdue Pharma said it accepted responsibility for false statements made about the drug's risks of addiction, abuse, withdrawal and tolerance six years ago, but added, "during the past six years, we have implemented changes to our internal training, compliance and monitoring systems that seek to assure that similar events do not occur again."

Generic firms, including Teva and Endo, had sold generic versions of Oxycontin, but have since stopped making the products and are not accused of any wrongdoing in connection with promoting their products, reports said.


'"/>




Related medicine news :

1. Misleading anti-malarial drug
2. Misleading Advertisements for Prescription Drugs
3. The Effects Of Smoking Misleading
4. Lifting The Screen off Misleading Sunscreen labels
5. Misleading Health Claims On Food Labels No Longer Allowed in EU
6. Walkers Crisps Advertisements make Misleading Claims about Salt Content
7. Medical Council Of India Draws Public Attention on Misleading Ads.
8. Obesity Drug Advertisements Misleading Teens
9. Labeling of Dairy Products with Trans fat labels, Misleading to Consumers
10. WHO Condemns Tobacco Industry for Misleading Public
11. Cancer Doctors Okays Controversial Prostate Therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... , ... HMP , a leader in healthcare events and education, today announced ... Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie ... competition recognizes editorial and design excellence across a range of sectors. This year’s program ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
Breaking Medicine Technology: